A股異動 | 寒武紀-U跌近11% 核心技術人員離職
格隆匯3月15日丨寒武紀-U(688256.SH)跌10.95%,報72.03億元,總市值289億元。
寒武紀-U14日公吿,公司核心技術人員梁軍因與公司存在分歧,通知公司解除勞動合同。根據梁軍與公司簽署的《勞動合同》約定以及《勞動合同法》的相關規定,公司已於近日為其辦理相關離職手續;離職後,梁軍將不再擔任本公司任何職務。梁軍的離職,會對公司的研發管理工作產生一定影響。公司已經建立了完備的研發體系,形成了專業的研發隊伍,儲備了豐富的專利技術,梁軍的離職不會影響公司的技術創新,不會對公司整體研發實力產生重大不利影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.